SCHEDULE 13G/A: Paul L. Berns Amends Beneficial Ownership in Neumora Therapeutics to 5.1%

Paul L. Berns has filed an amended Schedule 13G, disclosing a beneficial ownership of 5.1% in Neumora Therapeutics, Inc. as of December 31, 2024.

Summary

• Paul L. Berns, an individual, reported beneficial ownership of 8,226,272 shares of Neumora Therapeutics, Inc. Common Stock.
• This ownership represents 5.1% of the company's outstanding Common Stock.
• The calculation is based on 161,561,064 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q.
• The total beneficial ownership includes 7,247,625 record shares, 779,318 vested options, 156,517 options vesting within sixty days, and 42,812 restricted stock units vesting within sixty days.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the company's perceived financial or operational performance, thus maintaining a neutral sentiment.

Positives

• The filing provides transparency regarding a significant individual shareholder's stake in Neumora Therapeutics, Inc.

Future Outlook

The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard regulatory disclosure of a significant individual ownership stake in a publicly traded company, common across all industries. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the continued significant stake held by Paul L. Berns.

Key Dates

Keywords

Neumora Therapeutics, Paul L Berns, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Ownership Disclosure, 640979100